@article {1148, title = {In Quest of the Mysterious Holistic Vedic Herb Bacopa monnieri (L.) Pennell}, journal = {Pharmacognosy Research}, volume = {15}, year = {2023}, month = {June 2023}, pages = {410-454}, type = {Review Article}, chapter = {410}, abstract = {

Throughout history, complementary and alternative therapies have been widely utilised. In recent years, there has been a surge in interest in the usage of herbal treatments all around the world. Various natural chemicals, such as those produced from plants, have been investigated as potential therapies for a myriad of ailments. The essence of this review was to methodically describe everything we know about Bacopa monnieri (L.) Pennell, a mysterious holistic Vedic herb belonging to the Plantaginaceae family, a well-known nootropic and effective memory enhancer, which has recently emerged as one of the most important medical herbs, widely used therapeutically in the Orient and growing in popularity around the world. Literature was gathered from sources such as Scopus, PubMed, Google Scholar, and ScienceDirect, and reviewed using the Prisma quality metacritic paradigm. It is now plainly obvious that current therapies fall short of meeting the demands of the vast majority of individuals with health problems, and traditional medicines are gaining appeal as a result of their reduced toxicity. Bacopa is a traditional herb used in Ayurvedic medicine to treat brain and nerve weariness, as well as in Siddha medicine to treat impaired memory. It{\textquoteright}s also used to cure brain and nerve exhaustion in Unani medicine. We improved Brahmi micropropagation and secondary metabolite biosynthesis by compiling pharmacobotanical and pharmacognostical descriptions, as well as ethnoarchaeological data and nanotechnology domination. This critique also highlights our contemporary information of pharmacological activity, preclinical and clinical investigations, significant bioactives, reported mechanisms of action, clinical effectiveness, safety, and the potential for herb-drug interactions. At the same time, the current incarnation of research at the plant is reviewed, as well as future research possibilities. Brahmi offers a lot of potential for treating a range of illnesses, including neuro-pharmacological, depression, inflammation, hepatoprotective, antidiabetic, and others. According to the presumptions of this review, further clinical trials and research are needed. While the impact of Brahmi as an anxiolytic and antidepressant has to be explored further, its potential as an anti-epileptic therapy and a treatment for antiepileptic drugs side effects is also being researched. Furthermore, Brahmi{\textquoteright}s antioxidant ability may explain, at least in part, the antistress, immunomodulatory, cognition-facilitating, anti-inflammatory, and anti-aging benefits documented in experimental animals and clinical circumstances, necessitating further study into its other therapeutic characteristics.

}, keywords = {Bacopa monnieri, Cheminformatics, Clinical trials, Herpestis monnieri, Pharmacological Testimony, Phytomolecules., Plantaginaceae}, doi = {10.5530/pres.15.3.045}, author = {Sumanta Mondal and Kausik Bhar and Prasenjit Mondal and Naresh Panigrahi and Suvendu Kumar Sahoo and Pydi Swetha and Subhadip Chakraborty and Nooka Yaswanth Teja and Neha Parveen} } @article {269, title = {Mitochondrial Nephrotoxicity induced by Tacrolimus (FK-506) and Modulatory Effects of Bacopa monnieri (Farafakh) of Tabuk Region}, journal = {Pharmacognosy Research}, volume = {11}, year = {2019}, month = {February,2019}, pages = {20-24}, type = {Original Article}, chapter = {20}, abstract = {

Background: Tacrolimus is a known immunosuppressive drug used widely for organ transplantation, but its nephrotoxicity mechanism is still unclear. Objectives: The present study investigates the protective efficacy of Bacopa monnieri (BM), against tacrolimus-induced nephrotoxicity in rats. Materials and Methods: Group 1 (control group); administered orally with normal saline for 30 days; Group 2 (BM extract treated group); Group 3 (tacrolimus-treated group); and Group 4; (tacrolimus plus BM extract treated group). Tacrolimus-treated rats received 1 mg/kg body weight of tacrolimus intraperitoneally for 30 days, and BM-pretreated rats were administered with the dose of 200 mg/kg orally by gavage once a day for 30 days. Results: Tacrolimus-induced nephrotoxicity was assessed biochemically and histopathologically. Pretreatment with BM has shown to possess a significant protective effect against tacrolimus-induced kidney functions regarding urea, creatinine, and albumin levels, respectively. The creatinine, mitochondrial lipid peroxidation (thiobarbituric acid reactive substances), and protein carbonyl levels were significantly increased dramatically, and however, the total proteins, albumin, glutathione, superoxide dismutase, and glutathione peroxidase were decreased when pretreated with tacrolimus. The nephroprotective efficacy of the BM extract was further evident by histopathological analysis and DNA fragmentation. Conclusion: The outcome of this study indicates that BM extracts exerted protection against tacrolimus-induced kidney toxicity.

}, keywords = {Antioxidant activity, Bacopa monnieri, DNA fragmentation, Nephrotoxicity, Tacrolimus.}, doi = {10.4103/pr.pr_100_18}, author = {Atif Abdulwahab A. Oyouni and Shalini Saggu and Ehab Tousson and Anand Mohan and Abdullah Farasani} }